Registry for patients with Thrombotic Thrombocytopenic Purpura in Spain and Portugal

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to evaluate at least 300 patients diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) across multiple centers in Spain and Portugal. Conducted under standard clinical practice conditions, the study will collect data on treatment efficacy, morbidity, mortality, and potential neurocognitive and cardiac sequelae associated with TTP. Additionally, biological samples will be obtained to create a serum and DNA library for further research. The goal is to enhance understanding of TTP and improve patient outcomes through better management strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with diagnosis of TTP according to International Consensus criteria from centres in Spain and Portugal.
2. Patients that voluntarily sign the informed consent. For subjects unable to provide informed consent, a fully recognized medical authority may be used according to local laws.
3. Patients between 0 to 99 years old at the time of diagnosis.

Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.

Exclusion Criteria:

1. Inability to comply with study procedures and follow-up exams.
2. Patients with any type of alteration that compromises their ability to grant written informed consent.
3. Patients that do not consent to participate in the study and do not sign informed consent.
4. Patients that do not meet the criteria previously mentioned for TTP.

Where it's running

• Hospital Universitario Virgen del Rocío
  Seville, Andalusia, Spain Recruiting
• Hospital Universitario Bellvitge
  L'Hospitalet de Llobregat, Barcelona, Spain Recruiting
• Hospital Clínic Barcelona
  Barcelona, Spain Recruiting
• Hospital Universitario de Guadalajara
  Guadalajara, Spain Recruiting
• Hospital Universitario La Paz
  Madrid, Spain Recruiting
• Hospital Virgen de la Arrixaca
  Murcia, Spain Recruiting

Study contacts

• Study coordinator: Contact person Designated by the Sponsor
• Email: investigacion@mfar.net
• Phone: +34934344412

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• cTTP patients treated with recombinant ADAMTS13: what happened after the early access program

  This study looks at people with congenital TTP who received recombinant ADAMTS13 to see how treatment changes their health before and after use.

  Recruiting Takeda · Cologne, North Rhine-Westphalia and 7 other locations · NCT07429942

• Adzynma in people with congenital TTP: a look at safety and antibody risk

  This study checks whether people with congenital TTP who have already received Adzynma develop neutralizing antibodies against Adzynma within six months of starting treatment.

  Recruiting at 6 sites Takeda · Vienna and 6 other locations · NCT07353099

• Long-term outcomes for people with immune TTP in the French national TMA cohort

  This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07205861

• Understanding the immune response in Thrombotic Thrombocytopenic Purpura

  This study is trying to understand how certain immune cells behave in people with Thrombotic Thrombocytopenic Purpura to see if they can help predict relapses and improve treatment.

  Recruiting University Hospital, Rouen · Rouen · NCT06945861

• Survey of a treatment for congenital thrombotic thrombocytopenic purpura

  This study is testing a new treatment called recombinant ADAMTS13 to see if it helps people with congenital thrombotic thrombocytopenic purpura feel better and stay healthy over 18 months.

  Recruiting Takeda · Tokyo, Tokyo · NCT06441578

• Registry for patients with immune-mediated thrombotic thrombocytopenic purpura in Italy

  This study is tracking patients with immune-mediated thrombotic thrombocytopenic purpura in Italy to see how the disease affects them over time and what their treatment outcomes are.

  Recruiting Fondazione Luigi Villa · Milan, MI · NCT06376786

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.